

Houke M Klomp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9574868/publications.pdf>

Version: 2024-02-01

48
papers

1,789
citations

279798

23
h-index

265206

42
g-index

48
all docs

48
docs citations

48
times ranked

2642
citing authors

#	ARTICLE	IF	CITATIONS
1	Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1569-1576.	1.1	206
2	Spinal-cord stimulation in critical limb ischaemia: a randomised trial. <i>Lancet</i> , The, 1999, 353, 1040-1044.	13.7	174
3	The Relationship Between Volume or Surgeon Specialty and Outcome in the Surgical Treatment of Lung Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1170-1178.	1.1	119
4	Pulmonary Squamous Cell Carcinoma following Head and Neck Squamous Cell Carcinoma: Metastasis or Second Primary?. <i>Clinical Cancer Research</i> , 2005, 11, 6608-6614.	7.0	87
5	Feasibility of Pathology-Correlated Lung Imaging for Accurate Target Definition of Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 267-275.	0.8	85
6	Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2731-2738.	1.6	82
7	Is ¹⁸ F-FDG PET/CT Useful for the Early Prediction of Histopathologic Response to Neoadjuvant Erlotinib in Patients with Non-Small Cell Lung Cancer?. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1344-1348.	5.0	80
8	Microscopic Disease Extension in Three Dimensions for Non-Small-Cell Lung Cancer: Development of a Prediction Model Using Pathology-Validated Positron Emission Tomography and Computed Tomography Features. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 448-456.	0.8	69
9	Improved identification of peripheral lung tumors by using diffuse reflectance and fluorescence spectroscopy. <i>Lung Cancer</i> , 2013, 80, 165-171.	2.0	63
10	Management of large mediastinal masses: surgical and anesthesiological considerations. <i>Journal of Thoracic Disease</i> , 2016, 8, E175-E184.	1.4	58
11	Outcome After Surgical Resections of Recurrent Chest Wall Sarcomas. <i>Journal of Clinical Oncology</i> , 2008, 26, 5113-5118.	1.6	53
12	Real-time <i>In Vivo</i> Tissue Characterization with Diffuse Reflectance Spectroscopy during Transthoracic Lung Biopsy: A Clinical Feasibility Study. <i>Clinical Cancer Research</i> , 2016, 22, 357-365.	7.0	53
13	Diffuse Reflectance Spectroscopy: A New Guidance Tool for Improvement of Biopsy Procedures in Lung Malignancies. <i>Clinical Lung Cancer</i> , 2012, 13, 424-431.	2.6	48
14	Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma. <i>JAMA Oncology</i> , 2021, 7, e205865.	7.1	45
15	Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. <i>European Journal of Cardio-thoracic Surgery</i> , 2009, 36, 741-746.	1.4	38
16	FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. <i>World Journal of Radiology</i> , 2014, 6, 392.	1.1	37
17	Introduction of lymphangiography and percutaneous embolization of the thoracic duct in a stepwise approach to the management of chylous fistulas. <i>Head and Neck</i> , 2007, 29, 1017-1023.	2.0	36
18	A clinical audit in a multidisciplinary care path for thoracic surgery: An instrument for continuous quality improvement. <i>Lung Cancer</i> , 2012, 78, 270-275.	2.0	34

#	ARTICLE	IF	CITATIONS
19	Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases. <i>Lung Cancer</i> , 2017, 112, 134-139.	2.0	33
20	Neoadjuvant (Induction) Erlotinib Response in Stage IIIA Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4205-4207.	1.6	32
21	18F-Fluorodeoxyglucose Positron Emission Tomography versus Computed Tomography in Predicting Histopathological Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment in Resectable Non-Small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 2831-2837.	1.5	27
22	Transesophageal Endoscopic Ultrasound with Fine Needle Aspiration in the Preoperative Staging of Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2008, 14, 6259-6263.	7.0	26
23	Ligands of Epidermal Growth Factor Receptor and the Insulin-Like Growth Factor Family as Serum Biomarkers for Response to Epidermal Growth Factor Receptor Inhibitors in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1939-1948.	1.1	25
24	Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: Why pneumonectomy should be avoided. <i>Lung Cancer</i> , 2010, 68, 222-227.	2.0	24
25	Survival after surgical resection of pulmonary metastases and second primary squamous cell lung carcinomas in head and neck cancer. <i>Head and Neck</i> , 2009, 31, 220-226.	2.0	22
26	Local progression after radiofrequency ablation for pulmonary metastases. <i>Cancer</i> , 2011, 117, 3781-3787.	4.1	21
27	Necrotizing pneumonitis caused by postoperative pulmonary torsion. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2008, 7, 144-145.	1.1	20
28	Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy. <i>Clinical Lung Cancer</i> , 2015, 16, 320-324.	2.6	20
29	Timing of Metabolic Response Monitoring During Erlotinib Treatment in Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1081-1086.	5.0	19
30	The influence of provider characteristics on resection rates and survival in patients with localized non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 60, 441-451.	2.0	18
31	Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 547-556.	2.8	18
32	Optimal surgical management of pulmonary metastases: VATS versus thoracotomy. <i>Respirology</i> , 2016, 21, 188-190.	2.3	17
33	Concurrent high-dose radiotherapy with low-dose chemotherapy in patients with non-small cell lung cancer of the superior sulcus. <i>Radiotherapy and Oncology</i> , 2011, 101, 278-283.	0.6	15
34	Peri- and postoperative management of stage III Non Small Cell Lung Cancer: Which quality of care indicators are evidence-based?. <i>Lung Cancer</i> , 2016, 101, 129-136.	2.0	14
35	Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib. <i>World Journal of Surgical Oncology</i> , 2013, 11, 59.	1.9	12
36	Evaluation of 18F-FDG PET-CT for Differentiation of Pulmonary Pathology in an Approach of Outpatient Fast Track Assessment. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1226-1230.	1.1	11

#	ARTICLE	IF	CITATIONS
37	Local treatment of pulmonary metastases: from open resection to minimally invasive approach? Less morbidity, comparable local control. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 2312-2321.	2.4	9
38	Tumor heterogeneity on 18F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib. <i>Journal of Thoracic Disease</i> , 2016, 8, E200-E203.	1.4	9
39	Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up. <i>Annals of Nuclear Medicine</i> , 2016, 30, 362-368.	2.2	9
40	Pre- and postoperative care for stage III NSCLC: Which quality of care indicators are evidence-based?. <i>Lung Cancer</i> , 2016, 101, 120-128.	2.0	8
41	COUNTERPOINT: Is N2 Disease a Contraindication for Surgical Resection for Superior Sulcus Tumors? <i>Chest</i> , 2015, 148, 1375-1379.	0.8	4
42	eComment. Circulating tumour cells caused by surgical manipulation in patients with lung cancer. Is minimally invasive "no-touch" surgery the solution?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2014, 18, 783-783.	1.1	3
43	Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?. <i>Lung Cancer</i> , 2020, 150, 209-215.	2.0	2
44	Results of neoadjuvant chemo(radio)therapy and resection for stage IIIA non-small cell lung cancer in The Netherlands. <i>Acta Oncologica</i> , 2020, 59, 748-752.	1.8	2
45	Transcutaneous Oximetry, Laser Doppler Fluxmetry, and Capillary Microscopy: Variability in Patients with Advanced Atherosclerotic Disease of the Lower Extremity. <i>Vascular Surgery</i> , 2000, 34, 231-243.	0.3	1
46	Is Pneumonectomy Justified in Patients With Locally Advanced NSCLC and Persistent N2 Disease After Induction Chemotherapy?. <i>Annals of Thoracic Surgery</i> , 2009, 87, 990-991.	1.3	1
47	EGFR-TKI Treatment and Surgical Resection for Oligometastatic NSCLC?. <i>Onkologie</i> , 2009, 32, 627-628.	0.8	0
48	Rebuttal From Dr Li et al. <i>Chest</i> , 2015, 148, 1380-1381.	0.8	0